References
- Gorre M E, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P N, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880
- Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak M Z, Wen S C, Zon G, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726–736
- Hoelbl A, Kovacic B, Kerenyi M A, Simma O, Warsch W, Cui Y, et al. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 2006; 107: 4898–4906
- Ren S Y, Bolton E, Mohi M G, Morrione A, Neel B G, Skorski T. Phosphatidylinositol 3-kinase p85α subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences. Mol Cell Biol 2005; 25: 8001–8008
- Harir N, Pecquet C, Kerenyi M, Sonneck K, Kovacic B, Nyga R, et al. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood 2007; 109: 1678–1686
- Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick J S, Prie N, Verdier F, et al. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005; 106: 1063–1066
- Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas L C. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 2005; 30: 194–204
- Jou S T, Carpino N, Takahashi Y, Piekorz R, Chao J R, Carpino N, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110δ in signaling by the B-cell receptor complex. Mol Cell Biol 2002; 22: 8580–8591
- Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott R G, Kreibich R, et al. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 2006; 10: 77–87
- Kharas M G, Deane J A, Wong S, O'Bosky K R, Rosenberg N, Witte O N. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 2004; 103: 4268–4275
- Dunn G P, Bruce A T, Ikeda H, Old L J, Schreiber R D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991–998
- Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest 2004; 114: 1650–1658
- Kim N, Saudemont A, Webb L, Camps M, Ruckle T, Hirsch E, et al. The p110δ catalytic isoform of PI3K is a key player in NK cell development and cytokine secretion. Blood 2007; 110: 3202–3208
- Tassi I, Cella M, Gilfillan S, Turnbull I, Diacovo T G, Penninger J M, et al. p110γ and p110δ phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Immunity 2007; 27: 214–227